Management

Hans Schambye is a seasoned biotech entrepreneur with extensive experience in drug discovery and development. Previously, Hans served as the Chief Executive Officer of ReceptIcon from 2006 to 2009 and as the CEO of Gastrotech Pharma A/S from 2004 to 2006. Before joining Gastrotech, he was Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a US biotech company. Hans has co-founded several biotech companies, including ProFound Pharma A/S, a Danish biotech company, which was acquired by Maxygen in 2000. Prior to this he had a successful research career at Stanford University and Copenhagen University within the field of receptor biology. Hans holds an MD from Odense University and a PhD in Medical Sciences from Copenhagen University.

Anders Pedersen has served as Chief Operating Officer of the Galecto group since April 2013, including as Chief Operating Officer of Galecto, Inc. since 2020. Prior to joining Galecto, Anders served as senior vice president of development at CMC Biologics A/S from 2010 to 2013. Before CMC, he worked at ReceptIcon A/S as Chief Operating Officer from 2006 to 2009. Earlier in his career, Anders served as Vice President of Project and Portfolio Management at Lifecycle Pharma A/S from 2005 to 2006 and spent 13 years at Novo Nordisk. Additionally, he co-founded ProFound Pharma A/S, a Danish biotech company, which was acquired by Maxygen in 2000. Anders holds a BS in Chemical Engineering from Danish Technical University in Copenhagen.

Bertil Lindmark has had an extensive and successful career in the pharmaceutical industry, building up broad clinical development and regulatory experience globally, and significant expertise in research and development in both large and small pharmaceutical organizations. As Global VP Clinical Development for the Respiratory and Inflammation franchises at AstraZeneca, Bertil led development of Symbicort, one of the worlds’ leading respiratory brands, and many other respiratory and gastro-intestinal products. From 2010, he headed Global R&D at Almirall, involving 500 staff and the successful development and approval of several new drugs in the respiratory, gastro-intestinal, neuroscience and dermatological fields. In 2015 he joined ASLAN Pharmaceuticals in Singapore with a focus on cancer and atopic skin and lung diseases. Bertil holds an MD from Lund University, Sweden with specialties in internal medicine and gastroenterology, and obtained his PhD in molecular epidemiology from Lund University. In 2019, he was appointed visiting Professor Innovation and Entrepreneurship at the Institute of Medicine at Gothenburg University, Sweden.

Jon Freve brings more than 20 years of financial experience in the biotechnology sector. Prior to joining Galecto, Jon served as CFO and Treasurer of Spring Bank Pharmaceuticals, a publicly listed clinical stage biotechnology company, and before that, as Sr. Director of Finance at Santaris Pharma. He began his career at the Financial Accounting Standards Board (FASB) and PricewaterhouseCoopers, where he worked in audit and transaction services. Jon has worked on several successful initial public offerings, secondary offerings, mergers and acquisitions and is a certified public accountant. He holds a Bachelor’s degree in Business Administration from the University of Massachusetts Amherst.